ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Infectious Disease

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

11,034Medicare Part D Prescriptions Filled, Including Refills

Rank: 9 out of 198

$4.35M Total Retail Price of All Prescriptions

Rank: 2 out of 198

144 Patients Receiving at Least One Drug in Part D
14%Patients 65 Years and Older
97% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Florida
Lower avg

Schedule Two
Controlled Substances

15% of this provider’s 144 patients filled at least one prescription for a schedule two drug, compared to an average of 1%.

Schedule Three
Controlled Substances

40% of this provider’s 144 patients filled at least one prescription for a schedule three drug, compared to an average of 3%.

Risky Drugs to Seniors

1% of this provider’s 859 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 0%.

Brand Name Drugs

60% of this provider’s prescriptions were for brand-name drugs, compared to an average of 47%.

Prescription Price

$394 was the average price of a prescription from this provider, compared to $351 among peers.

Prescriptions per Patient

77 is the average number of prescriptions (including refills) per patient, compared to an average of 13.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Florida
NORVIR 785 75 1 1
TRUVADA 675 42 2 2
PREZISTA 456 22 3 4
CRESTOR 371 42 4 14
ISENTRESS 368 22 5 3
REYATAZ 303 43 6 8
KETOCONAZOLE 248 0 7 72
ACYCLOVIR 243 12 8 29
OMEPRAZOLE 234 16 9 7
TESTOSTERONE CYPIONATE 216 0 S3 10 10 90
LOVAZA 211 16 11 45
OXANDROLONE 206 0 10 12 94
EPZICOM 193 27 13 10
VALACYCLOVIR 183 0 14 50
ZOLPIDEM TARTRATE 169 0 15 17
NASONEX 147 0 16 148
INTELENCE 134 0 17 20
NEXIUM 132 13 18 40
LEXIVA 121 25 19 53
ATRIPLA 119 0 20 5
AMLODIPINE BESYLATE 119 0 20 12
AMMONIUM LACTATE 117 20 22 92
LOPERAMIDE 115 0 23 129
TRAZODONE HCL 113 0 24 65
KALETRA 111 0 25 19
GABAPENTIN 105 0 26 21
COMBIVENT 98 0 27 186
BUPROPION XL 92 0 28 116
LYRICA 92 0 28 57
IBUPROFEN 92 0 28 35
DIOVAN 91 25 31 78
ENALAPRIL MALEATE 87 0 32 47
PROAIR HFA 86 0 33 43
FAMOTIDINE 85 0 34 101
TRICOR 80 0 35 65
SINGULAIR 76 0 36 131
TRIAMCINOLONE ACETONIDE 75 0 37 86
LISINOPRIL 72 14 38 6
SYMBICORT 72 0 38 172
LIDODERM 70 0 40 170
METFORMIN HCL 70 20 40 15
TRAMADOL HCL 66 0 42 42
ATENOLOL 60 0 43 30
CLINDAMYCIN PHOSPHATE 59 0 44 217
FLUTICASONE PROPIONATE 56 0 45 59
MIRTAZAPINE 55 0 46 167
METOPROLOL SUCCINATE 54 0 47 44
ADVAIR DISKUS 54 0 47 87
ATORVASTATIN CALCIUM 54 0 47 22
DEXILANT 54 0 47 235
SELZENTRY 53 0 51 89
FUROSEMIDE 52 0 52 24
SUSTIVA 52 0 52 56
CYMBALTA 52 0 52 119
SYNTHROID 50 0 55 63
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.